Skip to main content
. 2022 May 6;15(3):367–377. doi: 10.1007/s40271-022-00578-8

Table 2.

Treatment benefits reported by patients in exit interviews following the SURPASS trials (N = 28)

Treatment benefitsa Patients reporting each type of treatment benefit
n (%)
Improved blood glucose/HbA1c 27 (96%)
Weight loss 26 (93%)
Decreased appetite 22 (79%)
Increased energy 22 (79%)
Improved sleep 8 (29%)
Improved blood pressure 6 (21%)
Psychological benefit 5 (18%)
Decreased nocturia 3 (11%)
Improved neuropathy 3 (11%)
Improved eyesight 2 (7%)
Increased ability to focus 2 (7%)

aThis column lists all treatment benefits reported by more than one of the 28 patients who participated in the exit interviews